The Relative Tolerance of Children and Adults to Anticancer Drugs
Daniel Glaubiger(National Institutes of Health), Richard S. Ungerleider(Unknown), Bart Kamen(Children's Hospital of Wisconsin), Daniel D. Von Hoff(Translational Genomics Research Institute), John S. Holcenberg(Children's of Alabama), Charles B. Pratt(St. Jude Children's Research Hospital)
Cited by 33
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
|New England Journal of Medicine|1999|1.2k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
|Annals of Oncology|1996|569